Kalamazoo, MI, United States of America

Eldridge Myles Glenn


Average Co-Inventor Count = 2.2

ph-index = 5

Forward Citations = 90(Granted Patents)


Company Filing History:


Years Active: 1977-1981

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Eldridge Myles Glenn: Innovator in Inflammation Treatment

Introduction

Eldridge Myles Glenn, a distinguished inventor based in Kalamazoo, MI, has made significant contributions to the field of pharmaceutical innovations. With a total of seven patents to his name, he has dedicated his career to developing effective therapies, particularly in the area of inflammation treatment.

Latest Patents

One of his notable inventions is a process for treating inflammation locally or topically. This innovative approach involves administering a compound characterized by a specific formula that includes variables such as M and M' being hydrogen, hydroxy, halogen, or lower alkyl of 1 to 3 carbon atoms, among others. This compound is designed to work in association with appropriate pharmaceutical carriers, providing a targeted and efficient method for treating inflammation.

Career Highlights

Eldridge Myles Glenn has dedicated his skills and expertise to The Upjohn Company, where he has been instrumental in advancing pharmaceutical research and development. His work has not only expanded the scope of treatment options available for patients but has also contributed to the overall success of the organization.

Collaborations

Throughout his career, Glenn has collaborated with various professionals, including notable coworkers such as William A. Callahan and Douglas L. Rector. These collaborations have fostered an environment of innovation and creativity, allowing for the cross-pollination of ideas and advancements in pharmaceutical technologies.

Conclusion

In closing, Eldridge Myles Glenn stands out as a prominent inventor whose work in inflammation treatment has significant implications for medical advancements. His dedication to innovation continues to benefit both the pharmaceutical industry and the patients who rely on effective treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…